US Patent

US12472258 — Pharmaceutical compositions comprising meloxicam

Formulation · Assigned to Axsome Therapeutics Inc · Expires 2038-05-18 · 12y remaining

Vulnerability score 43/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions that combine meloxicam with cyclodextrin and/or a carbonate or bicarbonate for oral administration to improve meloxicam's bioavailability.

USPTO Abstract

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T max of meloxicam of 3 hours or less.

Drugs covered by this patent

Patent Metadata

Patent number
US12472258
Jurisdiction
US
Classification
Formulation
Expires
2038-05-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Axsome Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.